

出國報告（出國類別：開會）

2024 捷克 WCIM 世界內科醫學會心得報告

服務機關：高雄榮民總醫院/心臟內科

姓名職稱：吳奕廷/主治醫師

派赴國家：捷克

出國期間：2024/10/28-2024/11/04

報告日期：2024/11/12

摘要

參與 WCIM 世界內科醫學會第 37 屆 2024 年會議，為重要國際會議。本次投稿論文探討心臟科指標及冠心症介入治療預後臨床問題，對於臨床具參考價值。代表本院參與並發表研究成果，不僅提升本院國際聲譽和能見度，也促進學術的跨國交流，是珍貴的學習機會。大會提供跨領域交流平台，透過講座和討論，不同專科醫師分享最新臨床經驗與研究成果。現場展示投稿海報，多為年輕醫師交流熱烈。透過互動，獲得實用的臨床心得，也對如何撰寫並投稿學術論文有更深入的理解。大會中講座內容豐富，從心臟病、腎臟病到多重共病的管理皆有涉及，啟發臨床中應用靈感。布拉格的歷史與文化氛圍為整個會議增添了獨特的魅力，是一場既豐富又啟發性的學習之旅。

關鍵字

內科醫學會

心臟科

冠心症介入治療

跨次專科討論

目次

一、目的	4
二、過程	4
三、心得及建議	4
附錄	6

一、目的

參與 WCIM 世界內科醫學會 37th 2024，投稿發表海報。WCIM 世界內科醫學會為內科重要會議，與台灣內科醫學會亦多有合作。本次投稿論文(Systemic inflammation markers and cardiac clinical outcome after percutaneous coronary intervention in chronic kidney disease patients)探討心臟科重要指標與冠心症介入之預後臨床問題。代表本院參加發表得以增進本院聲譽與國際參與、心臟科學術交流。且為本員珍貴之學習機會。

二、過程

第一天(10/28):交通行程

第二天(10/29):交通行程

第三天(10/30):WCIM 世界內科醫學會，參與大會開幕式，與世界各國前來布拉格參與的各次專科內科醫師交流。

第四天(10/31):WCIM 世界內科醫學會，E-poster 形式發表海報(Systemic inflammation markers and cardiac clinical outcome after percutaneous coronary intervention in chronic kidney disease patients)。研讀參閱其他 Poster，與其他海報發表者交流。

第五天(11/01):WCIM 世界內科醫學會，參與大堂學術發表如心臟衰竭新知。大會有現場測試 Lp(a)，多跨科如心臟內科、新陳代謝科、神經內科討論此項指標與各種臨床疾病的相關意義。

第六天(11/02):WCIM 世界內科醫學會，參與閉幕式。

第七天(11/03):交通行程

第八天(11/04):交通行程

三、心得及建議

(一)心得

此次參與 2024 WCIM 世界內科醫學會 37th，千里迢迢至捷克布拉格參加，是東歐的千年古都，

也是個相當國際化的城市。參與會場在城市的南郊，與市中心都是古老建築不同，此處較為現代化的建築外觀，室內空間很大也很新穎。最主要的大廳非常大，可容納千人。開幕式人潮眾多，來自世界各地的內科醫師齊聚一堂。至海報區，除了與自己發表的海報(Systemic inflammation markers and cardiac clinical outcome after percutaneous coronary intervention in chronic kidney disease patients)照相留念，也能就近研讀參閱其他人的發表著作，也有特殊有趣的臨床個案經驗分享。現場也很多其他投稿海報的內科醫師，大多都是年輕醫師，能就近交流臨床經驗與投稿論文的内容。這次大會的各種學術發表橫跨各次專科，而因為是世界內科醫學會，在大內科的架構之內也有很多跨科的議題討論例如「多重共病」和「肥胖治療」的議題。一項很特別的是，大會現場可以去測試自己的 Lp(a)，這是一個近期受到矚目的血脂指標，與心臟臨床預後高度相關，也跟神經內科、新陳代謝科專家有許多討論。最後一天的「改善治療依從性」和「智慧選擇」講座，強調了患者教育在提升療效中的重要性。總的來說，本次大會提供了跨領域的學術交流機會，透過多場講座和討論，我不僅學習到新的醫學知識，還激發了在臨床工作中應用這些新知的靈感。布拉格的歷史與文化氛圍更增添了整個會議的吸引力，是一次非常豐富且具有啟發性的學習之旅。

(二)建議:

1.促進跨領域合作，強化整合性照護

針對多重共病患者，建議建立跨科室合作模式，如設立多重共病門診或聯合門診，讓內科、心臟科、腎臟科等相關專科共同參與，提升患者的整體健康管理。

2.加強患者依從性教育，提升治療效果

根據會議中強調的治療依從性重要性，建議推廣患者教育課程，讓病人更了解其疾病及治療方式，並配合數位化的健康管理工具，以便病人追蹤和自我管理。

3. 促進內外部醫療資源共享，建立標準化流程

建議建立與其他醫院或醫療機構的合作平台，分享最新診療指南、流程與研究成果，形成資源共享和經驗交流的良好模式，確保患者能夠獲得標準化的優質醫療服務

4.持續改善內科醫學的品質與標準

建議根據國際大會上提出的最新內科醫學標準，對內部流程進行定期檢討與調整，確保醫院能夠與國際接軌，並為患者提供最優質的醫療服務。

附錄

30.10.2024 WEDNESDAY		31.10.2024 THURSDAY		1.11.2024 FRIDAY		2.11.2024 SATURDAY	
CONGRESS HALL 1	CONGRESS HALL 2	CONGRESS HALL 1	CONGRESS HALL 2	CONGRESS HALL 1	CONGRESS HALL 2	CONGRESS HALL 1	CONGRESS HALL 2
14:00 - 18:00 Welcome Reception (Lobby, Foyer, Hall 1 & 2)	8:00 - 9:00 For Medical & Non-Medical Staff (Registration, Accreditation, Exhibitor Meeting)	8:30 - 9:30 Registration (Lobby, Foyer, Hall 1 & 2)	9:00 - 10:00 Registration (Lobby, Foyer, Hall 1 & 2)	8:30 - 9:30 Registration (Lobby, Foyer, Hall 1 & 2)	9:00 - 10:00 Registration (Lobby, Foyer, Hall 1 & 2)	8:30 - 9:30 Registration (Lobby, Foyer, Hall 1 & 2)	9:00 - 10:00 Registration (Lobby, Foyer, Hall 1 & 2)
10:00 - 14:00 Laboratory & Diagnostic Techniques in the Management of Cardiovascular Disease (Lobby, Foyer, Hall 1 & 2)	10:00 - 12:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	10:00 - 12:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	10:00 - 12:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	10:00 - 12:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	10:00 - 12:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	10:00 - 12:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	10:00 - 12:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)
12:00 - 13:00 Lunch Break (Lobby, Foyer, Hall 1 & 2)	12:00 - 13:00 Lunch Break (Lobby, Foyer, Hall 1 & 2)	12:00 - 13:00 Lunch Break (Lobby, Foyer, Hall 1 & 2)	12:00 - 13:00 Lunch Break (Lobby, Foyer, Hall 1 & 2)	12:00 - 13:00 Lunch Break (Lobby, Foyer, Hall 1 & 2)	12:00 - 13:00 Lunch Break (Lobby, Foyer, Hall 1 & 2)	12:00 - 13:00 Lunch Break (Lobby, Foyer, Hall 1 & 2)	12:00 - 13:00 Lunch Break (Lobby, Foyer, Hall 1 & 2)
13:00 - 14:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	13:00 - 14:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	13:00 - 14:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	13:00 - 14:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	13:00 - 14:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	13:00 - 14:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	13:00 - 14:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	13:00 - 14:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)
14:00 - 15:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	14:00 - 15:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	14:00 - 15:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	14:00 - 15:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	14:00 - 15:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	14:00 - 15:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	14:00 - 15:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	14:00 - 15:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)
15:00 - 16:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	15:00 - 16:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	15:00 - 16:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	15:00 - 16:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	15:00 - 16:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	15:00 - 16:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	15:00 - 16:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	15:00 - 16:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)
16:00 - 17:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	16:00 - 17:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	16:00 - 17:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	16:00 - 17:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	16:00 - 17:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	16:00 - 17:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	16:00 - 17:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	16:00 - 17:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)
17:00 - 18:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	17:00 - 18:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	17:00 - 18:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	17:00 - 18:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	17:00 - 18:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	17:00 - 18:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	17:00 - 18:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)	17:00 - 18:00 Stroke & Neurology (Lobby, Foyer, Hall 1 & 2)




PRAGUE - THE CAPITAL OF INTERNAL MEDICINE 2024

Prognostic Value of Systemic Inflammation Markers in Chronic Kidney Disease Patients Receiving Percutaneous Coronary Intervention

Yi-Hong Wu, En-Hao Lai, Chun-Hao Yeh, Ying-Chun Li, Jin-Shuen Chen, Yao-Shen Chen, Feng-Yu Rao
Department of Cardiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Department of Business Management, Institute of Health Care Management, National Sun Yat-sen University, Kaohsiung, Taiwan

Population

1197 CKD patients with PCI treatment



Mean age of 67.6±11.2 years

Location/Settings

A tertiary PCI center in Taiwan
From 2013 to 2020, retrospective

Investigation




Systemic inflammation markers
(Neutrophil-lymphocyte ratio (NLR), Platelet-lymphocyte ratio (PLR), and Monocyte-lymphocyte ratio (MLR)) are calculated as the ratio of different cell counts. The blood samples were obtained at the time of admission before PCI.

Primary outcome

Major adverse cardiac events (all-cause mortality, myocardial infarction, ischemic stroke / TIA) at one-year follow-up.

Study Flowchart




The optimal cut-off values for NLR, PLR, and MLR were determined by receiver operating characteristic curve analysis.

Results

Multivariate Cox regression analysis revealed NLR ≥ 3.8 (HR 1.43, 95% CI 1.10-1.87, P=0.008) was independent predictors of MACE.

The NLR ≥ 3.8 or not was selected to categorize the patients into high and low inflammation groups. The high inflammation group showed a higher MACE rate (26.2% vs. 16.3%, P < 0.001). The difference in MACE was driven by all-cause death (11.7% vs. 4.5%, P<0.001) and MI (10.8% vs. 7.5%, P=0.044).

Table 1. Outcomes of CKD patients receiving PCI by inflammation status	
	High (NLR ≥ 3.8)
Overall MACE	26.2%
All-cause mortality	11.7%
Myocardial infarction	10.8%
Ischemic stroke / TIA	4.5%



Findings:

The Kaplan-Meier curve revealed that the high inflammation group was associated with a worse clinical outcome (log-rank P<0.001).

Neutrophil-lymphocyte ratio is a significantly predictive inflammation parameter for clinical cardiovascular outcome in CKD patients who received PCI.



